P. Edlund, “Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1”, AO, vol. 50, no. 3, pp. 329–337, Apr. 2011.